๐๐จ๐ฉ๐๐จ๐ง ๐๐๐๐ฅ๐ญ๐ก๐๐๐ซ๐ ๐๐๐๐๐ฌ ๐ฆ๐๐๐ก๐ข๐ง๐๐๐โ๐ฌ ๐ ๐ฎ๐ง๐๐ข๐ง๐ ๐๐จ๐ฎ๐ง๐ ๐๐ง๐...
๐
๐๐ ๐๐๐๐๐ฉ๐ญ๐ฌ ๐๐ฅ๐๐ฎ๐ค๐จ๐ฌ'๐ฌ ๐๐๐ ๐๐จ๐ซ ๐๐ฉ๐ข๐จ๐ฑ๐: ๐ ๐๐๐ฐ ๐๐ซ๐ ๐ข๐ง ๐๐๐ซ๐๐ญ๐จ๐๐จ๐ง๐ฎ๐ฌ ๐๐ซ๐๐๐ญ๐ฆ๐๐ง๐ญ
๐ The acceptance of Glaukos Corporationโs NDA for Epioxa marks a significant advancement in treating keratoconus, a condition where the cornea weakens and bulges, causing vision distortion. Epioxa offers a faster, non-invasive treatment option compared to traditional corneal cross-linking therapies, which require epithelium removal.
๐ฅ In the UK, patients have benefited from local access to corneal cross-linking at Musgrove Park Hospital, which has improved their vision and stabilized the condition. This procedure has a 95% success rate, providing hope for many patients with this debilitating disease.
